Heron Therapeutics, Inc. (HRTX): Price and Financial Metrics


Heron Therapeutics, Inc. (HRTX): $2.91

-0.26 (-8.20%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add HRTX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

HRTX POWR Grades


  • Growth is the dimension where HRTX ranks best; there it ranks ahead of 75.16% of US stocks.
  • The strongest trend for HRTX is in Growth, which has been heading up over the past 179 days.
  • HRTX's current lowest rank is in the Quality metric (where it is better than 10.39% of US stocks).

HRTX Stock Summary

  • HRTX's went public 34.61 years ago, making it older than 91.57% of listed US stocks we're tracking.
  • With a year-over-year growth in debt of 548.06%, Heron Therapeutics Inc's debt growth rate surpasses 97.42% of about US stocks.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for HRTX comes in at -25.94% -- higher than that of only 14.95% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Heron Therapeutics Inc, a group of peers worth examining would be CCXI, CLSN, HTBX, ABEO, and OLED.
  • Visit HRTX's SEC page to see the company's official filings. To visit the company's web site, go to www.herontx.com.

HRTX Valuation Summary

  • In comparison to the median Healthcare stock, HRTX's price/earnings ratio is 113.97% lower, now standing at -5.1.
  • Over the past 243 months, HRTX's EV/EBIT ratio has gone down 11.1.
  • Over the past 243 months, HRTX's EV/EBIT ratio has gone down 11.1.

Below are key valuation metrics over time for HRTX.

Stock Date P/S P/B P/E EV/EBIT
HRTX 2021-08-31 14.3 7.4 -5.1 -4.9
HRTX 2021-08-30 14.3 7.4 -5.1 -4.9
HRTX 2021-08-27 14.2 7.4 -5.0 -4.9
HRTX 2021-08-26 14.1 7.3 -5.0 -4.8
HRTX 2021-08-25 14.3 7.4 -5.1 -4.9
HRTX 2021-08-24 14.1 7.3 -5.0 -4.9

HRTX Growth Metrics

    The year over year revenue growth rate now stands at -40.43%.
  • Its 5 year net income to common stockholders growth rate is now at -75%.
  • The 5 year net cashflow from operations growth rate now stands at -18.95%.
Over the past 34 months, HRTX's revenue has gone down $11,163,000.

The table below shows HRTX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 86.346 -203.354 -220.683
2021-09-30 86.296 -210.65 -228.318
2021-06-30 83.031 -199.538 -234.138
2021-03-31 83.256 -193.823 -228.313
2020-12-31 88.638 -184.82 -227.278
2020-09-30 103.116 -159.243 -222.917

HRTX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • HRTX has a Quality Grade of D, ranking ahead of 9.05% of graded US stocks.
  • HRTX's asset turnover comes in at 0.243 -- ranking 181st of 682 Pharmaceutical Products stocks.
  • IBIO, COLL, and PTGX are the stocks whose asset turnover ratios are most correlated with HRTX.

The table below shows HRTX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.243 0.485 -0.993
2021-06-30 0.228 0.515 -1.093
2021-03-31 0.224 0.582 -1.080
2020-12-31 0.214 0.592 -0.933
2020-09-30 0.227 0.586 -0.779
2020-06-30 0.277 0.581 -0.676

HRTX Price Target

For more insight on analysts targets of HRTX, see our HRTX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $33.00 Average Broker Recommendation 1.42 (Moderate Buy)

HRTX Stock Price Chart Interactive Chart >

Price chart for HRTX

HRTX Price/Volume Stats

Current price $2.91 52-week high $16.16
Prev. close $3.17 52-week low $2.19
Day low $2.91 Volume 310,396
Day high $3.19 Avg. volume 2,415,176
50-day MA $3.56 Dividend yield N/A
200-day MA $7.50 Market Cap 298.22M

Heron Therapeutics, Inc. (HRTX) Company Bio


Heron Therapeutics is a biotechnology company focused on improving the lives of patients by developing best-in-class medicines that address major unmet medical needs. The company was founded in 1983 and is based in Redwood City, CA.


HRTX Latest News Stream


Event/Time News Detail
Loading, please wait...

HRTX Latest Social Stream


Loading social stream, please wait...

View Full HRTX Social Stream

Latest HRTX News From Around the Web

Below are the latest news stories about Heron Therapeutics Inc that investors may wish to consider to help them evaluate HRTX as an investment opportunity.

Short Sellers Were Right About These 10 Stocks

In this article, we discuss the 10 stocks that short sellers were right about. If you want to skip our detailed analysis of these stocks, go directly to Short Sellers Were Right About These 5 Stocks. Short-sellers were the headliners of early 2021. A year later, these short-sellers are once again in the spotlight amid […]

Yahoo | February 24, 2022

Heron Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on Monday, February 28, 2022

Heron Therapeutics, Inc. (Nasdaq: HRTX) a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that the company will host a conference call and live webcast on Monday, February 28, 2022 at 4:30 p.m. ET to report fourth quarter and full year 2021 financial results and discuss recent business highlights.

Yahoo | February 22, 2022

Strong week for Heron Therapeutics (NASDAQ:HRTX) shareholders doesn't alleviate pain of three-year loss

It's nice to see the Heron Therapeutics, Inc. ( NASDAQ:HRTX ) share price up 12% in a week. But that is small...

Yahoo | February 11, 2022

Twin Lakes Capital Management, LLC Buys Matterport Inc, DocuSign Inc, Teladoc Health Inc, Sells ...

Investment company Twin Lakes Capital Management, LLC (Current Portfolio) buys Matterport Inc, DocuSign Inc, Teladoc Health Inc, Blackrock Debt Strategies Fund Inc, Invesco Senior Income Trust, sells Alibaba Group Holding, Cango Inc, , Heron Therapeutics Inc, Air Products & Chemicals Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Twin Lakes Capital Management, LLC.

Yahoo | February 7, 2022

Integral Health Asset Management, LLC Buys McKesson Corp, Centene Corp, Abbott Laboratories, ...

Investment company Integral Health Asset Management, LLC (Current Portfolio) buys McKesson Corp, Centene Corp, Abbott Laboratories, Biogen Inc, Amedisys Inc, sells Arena Pharmaceuticals Inc, Medtronic PLC, Hologic Inc, Zimmer Biomet Holdings Inc, Acadia Healthcare Co Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Integral Health Asset Management, LLC.

Yahoo | February 2, 2022

Read More 'HRTX' Stories Here

HRTX Price Returns

1-mo -11.82%
3-mo -51.90%
6-mo -68.13%
1-year -81.25%
3-year -84.64%
5-year -78.99%
YTD -68.13%
2021 -56.86%
2020 -9.94%
2019 -9.41%
2018 43.31%
2017 38.17%

Continue Researching HRTX

Here are a few links from around the web to help you further your research on Heron Therapeutics Inc's stock as an investment opportunity:

Heron Therapeutics Inc (HRTX) Stock Price | Nasdaq
Heron Therapeutics Inc (HRTX) Stock Quote, History and News - Yahoo Finance
Heron Therapeutics Inc (HRTX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6154 seconds.